Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

French Childhood Cancer Survivor Study

NCT01620372 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2011-11-15
Last updated
2026-07-30

Condition(s) studied

Childhood Solid Tumor

Study summary

The FCCSS is a multicentric national large-scale collaborative population-based study of children treated for a solid tumor before 2000 in France and before the age of 19 years.

The study is concerned by improving knowledge about the long-term effects caused by cancer and its treatments including adverse health and social outcomes.

The main reason of the FCCSS is to estimate the risk of adverse health and social outcomes that may occur after a cancer treatment and to prevent them by providing adapted follow-up care.

The cohort will be followed for up to 20 years from 2011.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * All types of solid childhood cancer in France * Age at diagnosis: Below age 19 * Period of diagnosis: between 1st January 1942 and 31st December 1999 * Complete identification (first name, last name, date of birth and place of birth) Exclusion Criteria: * Leukaemia cases

Primary outcome measure(s)

  • All health events of interest — by time since diagnosis of solid childhood cancer
    * all causes mortality (e.g. cerebrovascular, cardiovascular,...) * all iatrogenic events (e.g. diabetes, thyroid adenomas, cardiac diseases, second malignant solid tumors, secondary leukemia,...)

Trial sites (36)

FacilityCityRegionStatus
Centre Hospital-Universitaire Hôpital Nord Amiens France Active Not Recruiting
Centre Hospitalier-Universitaire Angers France Active Not Recruiting
Centre Hospitalier Régional Universitaire Hôpital Saint-Jacques Besançon France Active Not Recruiting
Groupe hospitalier Pellegrin Bordeaux France Active Not Recruiting
Centre Hospitalier Universaitaire Hôpital Côte de Nacre Caen France Active Not Recruiting
Centre Hospitalier Universitaire Hôpial Hôtel Dieu Clermont-Ferrand France Active Not Recruiting
Centre Hospitalier Universaitaire hôpital d'enfants Dijon France Active Not Recruiting
Hôpital La Tronche Grenoble France Active Not Recruiting
Centre Oscar Lambret Lille France Active Not Recruiting
Hôpital Jeanne De Flandre Lille France Active Not Recruiting
Hôpital de la mère et de l'enfant Limoges France Active Not Recruiting
Institut d'Hématologie et Oncologie Pédiatrique Lyon France Active Not Recruiting
Centre Régional de Lutte Contre le Cancer Centre Léon Bérard Lyon France Active Not Recruiting
Hôpital d'Enfants de Margency (HEM) Croix Rouge Française Margency France Active Not Recruiting
AP-HM Hôpital de la Timone Marseille France Active Not Recruiting
Hôpital Arnaud De Villeneuve Montpellier France Active Not Recruiting
Centre Hospitalier Universaitaire Hôpital mère-enfant Nantes France Active Not Recruiting
Centre Antoine Lacassagne Nice France Recruiting
GCS Hôpitaux pédiatriques Centre Hospitalier Universitaire Lenval Nice France Active Not Recruiting
Institut Curie Paris France Recruiting
Hôpital Armand Trousseau Paris France Active Not Recruiting
CHRU de Poitiers La Miletrie Poitiers France Active Not Recruiting
Institut Jean Godinot Reims France Recruiting
Centre Hospitalier Universitaire de Reims Hôpital Maison Blanche Reims France Active Not Recruiting
Centre Hospitalier Universitaire Hôpital Sud Rennes France Active Not Recruiting
Hôpital Charles-Nicolle Rouen France Active Not Recruiting
Centre Hospitalier Universitaire Hôpital Nord Saint-Etienne France Active Not Recruiting
Centre René Gauducheau de Nantes Atlantique Saint-Herblain France Active Not Recruiting
Centre Hospitalier de Saintonge Saintes France Active Not Recruiting
Hôpital Hautepierre Strasbourg France Active Not Recruiting
Institut Claudius Regaud Toulouse France Recruiting
Hôpital des Enfants Toulouse France Active Not Recruiting
Hôpital Clocheville Tours France Active Not Recruiting
Hôpital Brabois enfants CHU de Nancy Vandœuvre-lès-Nancy France Active Not Recruiting
Centre Régional de Lutte Contre le Cancer de Lorraine ALEXIS VAUTRIN Vandœuvre-lès-Nancy France Active Not Recruiting
Institut Gustave Roussy Villejuif France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01620372 on ClinicalTrials.gov ↗ ← All trials in France